{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T21:57:32Z","timestamp":1747173452629,"version":"3.40.5"},"reference-count":18,"publisher":"Cambridge University Press (CUP)","issue":"1","license":[{"start":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T00:00:00Z","timestamp":1705017600000},"content-version":"unspecified","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Technol Assess Health Care"],"published-print":{"date-parts":[[2024]]},"abstract":"Abstract<\/jats:title>\n\t \n\t Objectives<\/jats:title>\n\t In the UK, the number of patients urgently referred for suspected cancer is increasing, and providers are struggling to cope with demand. We explore the potential cost-effectiveness of a new risk prediction test \u2013 the PinPoint test \u2013 to triage and prioritize patients urgently referred with suspected urological cancers.<\/jats:p>\n\t <\/jats:sec>\n\t \n\t Methods<\/jats:title>\n\t Two simulation models were developed to reflect the diagnostic pathways for patients with (i) suspected prostate cancer, and (ii) bladder or kidney cancer, comparing the PinPoint test to current practice. An early economic analysis was conducted from a UK National Health Service (NHS) perspective. The primary outcomes were the percentage of individuals seen within 2 weeks and health care costs. An exploratory analysis was conducted to understand the potential impact of the Pinpoint test on quality-adjusted life years gained.<\/jats:p>\n\t <\/jats:sec>\n\t \n\t Results<\/jats:title>\n\t Across both models and applications, the PinPoint test led to more individuals with urological cancer being seen within 2 weeks. Using PinPoint only to prioritize patients led to increased costs overall, whereas using PinPoint to both triage and prioritize patients led to cost savings. The estimated impact on life years gained\/lost was very small and highly uncertain.<\/jats:p>\n\t <\/jats:sec>\n\t \n\t Conclusions<\/jats:title>\n\t Using the PinPoint test to prioritize urgent referrals meant that more individuals with urological cancer were seen within 2 weeks, but at additional cost to the NHS. If used as a triage and prioritization tool, the PinPoint test shortens wait times for referred individuals and is cost saving. More data on the impact of short-term delays to diagnosis on health-related quality of life is needed.<\/jats:p>\n\t <\/jats:sec>","DOI":"10.1017\/s0266462324000023","type":"journal-article","created":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T07:20:02Z","timestamp":1707117602000},"source":"Crossref","is-referenced-by-count":0,"title":["The National Health Service urgent cancer referral pathway for suspected urological cancers: early economic evaluation of a risk prediction test"],"prefix":"10.1017","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0652-6877","authenticated-orcid":false,"given":"Paola","family":"Cocco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7709-1869","authenticated-orcid":false,"given":"Alison Florence","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard D.","family":"Neal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bethany","family":"Shinkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2024,1,12]]},"reference":[{"key":"S0266462324000023_r2","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp22X718217"},{"key":"S0266462324000023_r8","unstructured":"8. National Cancer Registration and Analysis Service (NCRAS). Routes to diagnosis 2013\u20132016 2018. Available from: http:\/\/www.ncin.org.uk\/publications\/routes_to_diagnosis."},{"key":"S0266462324000023_r4","unstructured":"4. NHS England. Quarterly provider based cancer waiting times statistics 2023. Available from: https:\/\/www.england.nhs.uk\/statistics\/statistical-work-areas\/cancer-waiting-times\/quarterly-prov-cwt\/."},{"key":"S0266462324000023_r5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-053590"},{"key":"S0266462324000023_r13","unstructured":"13. Bank of England. Inflation calculator. Available from: https:\/\/www.bankofengland.co.uk\/monetary-policy\/inflation\/inflation-calculator."},{"key":"S0266462324000023_r14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30392-2"},{"key":"S0266462324000023_r1","unstructured":"1. National Institute for Health and Care Excellence. Suspected cancer: Recognition and referral guidelines 2015. Available from: https:\/\/www.nice.org.uk\/guidance\/ng12\/resources\/suspected-cancer-recognition-and-referral-pdf-1837268071621."},{"volume-title":"Unit costs of health and social care 2020","year":"2020","author":"Curtis","key":"S0266462324000023_r12"},{"key":"S0266462324000023_r6","unstructured":"6. National Institute for Health and Care Excellence. Prostate cancer: Diagnosis and management guidelines 2019. Available from: https:\/\/www.nice.org.uk\/guidance\/ng131\/resources\/prostate-cancer-diagnosis-and-management-pdf-66141714312133."},{"key":"S0266462324000023_r3","unstructured":"3. UK Statutory Instruments. National Health Service Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012. 2012. Available from: https:\/\/www.legislation.gov.uk\/uksi\/2012\/2996\/made\/data.pdf."},{"key":"S0266462324000023_r17","doi-asserted-by":"publisher","DOI":"10.1177\/09691413211059638"},{"key":"S0266462324000023_r18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0279227"},{"key":"S0266462324000023_r15","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2023.3798"},{"key":"S0266462324000023_r10","unstructured":"10. NHS England. 2019\/20 national cost collection data publication 2021. Available from: https:\/\/www.england.nhs.uk\/publication\/2019-20-national-cost-collection-data-publication\/."},{"key":"S0266462324000023_r11","unstructured":"11. NHS England. 2020\/21 national cost collection data publication 2021. Available from: https:\/\/www.england.nhs.uk\/costing-in-the-nhs\/national-cost-collection\/#ncc1819."},{"key":"S0266462324000023_r7","unstructured":"7. National Institute for Health and Care Excellence. Bladder cancer: Diagnosis and management guidelines 2015. Available from: https:\/\/www.nice.org.uk\/guidance\/ng2\/resources\/bladder-cancer-diagnosis-and-management-pdf-51036766405."},{"key":"S0266462324000023_r16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00731-5"},{"key":"S0266462324000023_r9","unstructured":"9. NHS England. Monthly provider based data and summaries waiting times 2023. Available from: https:\/\/www.england.nhs.uk\/statistics\/statistical-work-areas\/cancer-waiting-times\/monthly-prov-cwt\/."}],"container-title":["International Journal of Technology Assessment in Health Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0266462324000023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T07:20:09Z","timestamp":1707117609000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0266462324000023\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024]]}},"alternative-id":["S0266462324000023"],"URL":"https:\/\/doi.org\/10.1017\/s0266462324000023","relation":{},"ISSN":["0266-4623","1471-6348"],"issn-type":[{"type":"print","value":"0266-4623"},{"type":"electronic","value":"1471-6348"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"e9"}}